TREA

86104198 - GENEQURE

Follow

Information

  • Trademark
  • 86104198
  • Serial Number
    86104198
  • Registration Number
    4741698
  • Filing Date
    October 29, 2013
    11 years ago
  • Registration Date
    May 26, 2015
    9 years ago
  • Transaction Date
    January 11, 2022
    3 years ago
  • Status Date
    December 03, 2021
    3 years ago
  • Published for Opposition Date
    September 30, 2014
    10 years ago
  • Location Date
    May 26, 2015
    9 years ago
  • Status Code
    710
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    COLEMAN, NICHOLAS A
  • Attorney Name
    Zachary A. Aria
    Law Office Assigned Location Code
    M60
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
GENEQURE
Case File Statements
  • GS0011: Viral assays, viral reagents, viral preparations, gene therapy assays, gene therapy reagents, gene therapy preparations, nucleic acid delivery assays, nucleic acid delivery reagents, nucleic acid delivery preparations, viral vectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors, all for non-medical research purposes
  • GS0051: Viral medicines, gene therapy medicines, nucleic acid delivery medicines, viralvectors, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors and nucleic acid delivery vectors for medical purposes all for medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single genedisorders and cancers; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inheriteddisorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy and cell therapy, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single genedisorders and cancers; clinical medicalreagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; pharmaceutical preparations, vaccines, prophylaxis medicines and other pharmaceutical preparations all for use in nucleic acid-based therapy, gene therapy and cell therapy in the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers
  • GS0421: Research, product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science,chemistry and biochemistry
  • GS0441: Gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders,muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders
Case File Event Statements
  • 12/3/2021 - 3 years ago
    29 - CANCELLED SEC. 8 (6-YR) Type: C8..
  • 5/26/2020 - 4 years ago
    28 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1
  • 5/26/2015 - 9 years ago
    27 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 1/20/2015 - 10 years ago
    26 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B
  • 12/1/2014 - 10 years ago
    25 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN
  • 1/15/2015 - 10 years ago
    24 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 12/1/2014 - 10 years ago
    23 - TEAS POST PUBLICATION AMENDMENT RECEIVED Type: EPPA
  • 11/25/2014 - 10 years ago
    22 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 9/30/2014 - 10 years ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 9/30/2014 - 10 years ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 9/10/2014 - 10 years ago
    19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 8/22/2014 - 10 years ago
    18 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 8/21/2014 - 10 years ago
    17 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 8/15/2014 - 10 years ago
    16 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/15/2014 - 10 years ago
    15 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/8/2014 - 10 years ago
    14 - TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Type: ERSI
  • 8/6/2014 - 10 years ago
    13 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3
  • 8/6/2014 - 10 years ago
    12 - LETTER OF SUSPENSION E-MAILED Type: GNSL
  • 8/6/2014 - 10 years ago
    11 - SUSPENSION LETTER WRITTEN Type: CNSL
  • 7/25/2014 - 10 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 7/25/2014 - 10 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/25/2014 - 10 years ago
    8 - ASSIGNED TO LIE Type: ALIE
  • 7/24/2014 - 10 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 2/23/2014 - 10 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 2/23/2014 - 10 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 2/23/2014 - 10 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/14/2014 - 10 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 11/5/2013 - 11 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 11/1/2013 - 11 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP